Vioxx, also known as refecoxib, is a prescription COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) that was approved by FDA in May 1999 for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain in adults, and for the treatment of menstrual symptoms.
Vioxx was withdrawn from U.S. drugstores in September 2004 after a Merck study showed that long-term users of the drug had twice the risk of heart attack and stroke.
Use of study drugs in a large, federally funded Alzheimer prevention trial has been suspended following a decision by the study's leadership on Dec. 17, 2004.
The pharmaceutical and biotechnology industries face further marketing and sales challenges in 2005 as the fallout from the Vioxx and Celebrex market recall and warning make it increasingly challenging for companies across the industry to reach physicians and consumers with effective campaigns without the distractions of the unfavorable press these recent events have generated.
Women recovering from hysterectomies require less morphine to combat pain and are able to recover their lung function more quickly when they receive a combination of two non-morphine-like or “non-opioid” drugs as part of their treatment, a new Queen’s study shows.
Adverse events of long term medication with NSAIDs and particularly coxibs, has recently received much attention in the Vioxx matter. Consequently, Vioxx has been withdrawn and Prexige has been withheld from the market. The whole group of coxibs, are now under special observation by drug agencies in both Europe and the United States.
The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.
An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.
Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.
The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.
The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.
The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).
In light of several recent drug industry scandals roiling the nation's public health and raising serious questions about the US bodies that license and regulate the industry -- and startling new revelations today concerning National Institutes of Health (NIH) officials and the safety of a brand name AIDS drug used to prevent mother-to-child transmission of the HIV
In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.
A clinical study recently published in The Journal of Rheumatology concludes that a topical cream consisting of a blend of natural oils called cetylated fatty acids significantly increased range of motion and physical performance in patients with osteoarthritis of the knee with no reported side effects.
The Food and Drug Administration (FDA) tried to discredit one of its own experts after he told a US Senate hearing that the FDA had failed to protect the public over rofecoxib (Vioxx), according to two articles published online by the British Medical Journal.
AIDS Healthcare Foundation (AHF), today noted that the current "FDA fiasco" involving the agency's initial approval and subsequent recall of Merck's troubled arthritis drug, Vioxx, raises serious questions about the FDA's ongoing parallel role in the approval of generic AIDS drugs for widespread use in Africa and the developing world.
For the past several weeks, various allegations and characterizations have circulated and been reported on regarding FDA's approval and post market review of the drug Vioxx, a "Cox-2 inhibitor," that its sponsor, Merck, voluntarily withdrew from the market September 30th, 2004.
People in search of pain relief who take the generic anti-inflammatory etodolac suffer 60 percent fewer gastrointestinal complications than those who take similar drugs, according to researchers at UT Southwestern Medical Center at Dallas and the Dallas Veterans Affairs Medical Center.
With the support of the National Research Programme (Musculoskeletal Health - Chronic Pain) , researchers at the University of Berne analysed the data in publicly available studies on the anti-inflammatory drug Vioxx.
Pharmaceutical companies slashed their promotional spending for hormone therapies by more than a third following reports in July 2002 of health risks associated with the drugs, but within the year they beefed up their marketing efforts to promote lower-dose forms of the medications
Following the worldwide withdrawal of Vioxx (rofecoxib), the European Medicines Agency (EMEA) has been asked by the European Commission, as a precautionary measure, to conduct a review of COX-2 inhibitor medicines.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.